Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: out_of_the_loop who wrote (4581)	11/2/1999 12:15:00 AM
From: Kevin Podsiadlik	Read Replies (1) \| Respond to of 10293

BTW, Kevin's statement about the NEJM and prepublished material is not entirely correct. Specifically, material that has been presented at a conference (as the Gel Tech study was) is ,not prohibited from publishing there. If you look at the details of the NEJM guidelines for authors - they are on the web and in every issue, you will see that I am correct. While it is true that there are exceptions to the Ingelfinger Rule, submission to another journal such as the AJIC is decidedly not one of them. Indeed one would presume that GUMM had either had the study rejected or had voluntarily withdrawn it from the NEJM review process prior to submission to the AJIC, lest they be seen as acting in bad faith with respect to the NEJM. Just wanted to make sure that was clear.